Ipamorelin vs GHRP-2

Verdict: GHRP-2 releases more growth hormone per dose; ipamorelin releases it more cleanly. GHRP-2 raises cortisol and prolactin measurably and stimulates appetite, while ipamorelin does almost none of that at standard doses. For anyone whose goals are sleep, recovery and body composition without hormonal side effects, ipamorelin is the modern default. GHRP-2 keeps a niche for people prioritizing maximum GH output or needing the appetite boost.

Side by side

IpamorelinGHRP-2
Typical dose200 mcg–300 mcg100 mcg–300 mcg
Frequency1–3x daily, often before bed1–3x daily
Administrationsubcutaneous injectionsubcutaneous injection
Common vials5 mg, 10 mg5 mg
Typical mix5 mg + 2 ml water5 mg + 2 ml water
Units for typical dose12 units (300 mcg)8 units (200 mcg)

Same receptor, different selectivity

Both are ghrelin-receptor agonists that trigger a pituitary GH pulse. GHRP-2 is the stronger agonist and also activates the receptor in tissues that drive cortisol, prolactin and hunger. Ipamorelin was engineered specifically to keep the GH effect while dropping those — Novo Nordisk's own studies showed no meaningful ACTH/cortisol rise at GH-releasing doses.

Dosing

Ipamorelin: 200–300 mcg per injection, 1–3× daily. GHRP-2: 100–300 mcg per injection on a similar schedule, with the 100 mcg 'saturation dose' being the classic reference. Both are almost always paired with a GHRH analog (CJC-1295 no DAC or sermorelin), which roughly doubles the GH pulse compared to either alone.

Side-effect profile decides it

GHRP-2 users report hunger within minutes of injection, water retention and occasional tiredness — signs of the cortisol/prolactin activity. Ipamorelin users mostly report flushing or a brief headache. Desensitization is also faster with GHRP-2 under continuous daily use.

Can you stack them?

Both pair with CJC-1295 (no DAC). Running ipamorelin and GHRP-2 together is uncommon — they compete for the same receptor — though some protocols rotate them to limit tolerance.

More comparisons

Educational comparison based on commonly published research protocols — not medical advice or an endorsement of any compound.